Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

Graves’ orbitopathy (GO) is the most common extrathyroidal manifestation of Graves’ disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label multicenter study of glucocorticoid-resistant GO treated with TCZ. The...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Med
Main Authors: Sánchez-Bilbao, Lara, Martínez-López, David, Revenga, Marcelino, López-Vázquez, Ángel, Valls-Pascual, Elia, Atienza-Mateo, Belén, Valls-Espinosa, Beatriz, Maiz-Alonso, Olga, Blanco, Ana, Torre-Salaberri, Ignacio, Rodríguez-Méndez, Verónica, García-Aparicio, Ángel, Veroz-González, Raúl, Jovaní, Vega, Peiteado, Diana, Sánchez-Orgaz, Margarita, Tomero, Eva, Toyos-Sáenz de Miera, Francisco J., Pinillos, Valvanera, Aurrecoechea, Elena, Mora, Ángel, Conesa, Arantxa, Fernández-Prada, Manuel, Troyano, Juan A., Calvo-Río, Vanesa, Demetrio-Pablo, Rosalía, González-Mazón, Íñigo, Hernández, José L., Castañeda, Santos, González-Gay, Miguel Á., Blanco, Ricardo
格式: Artigo
語言:Inglês
出版: MDPI 2020
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563792/
https://ncbi.nlm.nih.gov/pubmed/32878150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092816
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍